Back to Search Start Over

Role of type I receptors for anti-Müllerian hormone in the SMAT-1 Sertoli cell line

Authors :
Nathalie di Clemente
Corinne Belville
Soazik P. Jamin
Jean-Yves Picard
Nathalie Josso
Génétique, Reproduction et Développement (GReD)
Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM)
Institut de recherche en santé, environnement et travail (Irset)
Université d'Angers (UA)-Université de Rennes 1 (UR1)
Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Endocrinologie et Génétique de la Reproduction et du Développement
Université Paris-Sud - Paris 11 (UP11)-IFR13-Institut National de la Santé et de la Recherche Médicale (INSERM)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS)
Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Source :
Oncogene, Oncogene, Nature Publishing Group, 2005, 24 (31), pp.4984-4992. ⟨10.1038/sj.onc.1208686⟩, Oncogene, 2005, 24 (31), pp.4984-4992. ⟨10.1038/sj.onc.1208686⟩
Publication Year :
2005
Publisher :
HAL CCSD, 2005.

Abstract

International audience; Anti-Müllerian hormone (AMH) is a member of the transforming growth factor-beta family responsible for regression of Müllerian ducts during male sexual differentiation and for regulation of gonadal steroidogenesis. AMH is also a gonadal tumor suppressor which mediates its effects through a specific type II receptor and the bone morphogenetic protein (BMP)-specific Smad proteins, suggesting that AMH and BMPs could also share type I receptors, namely activin-like kinases (ALKs)2, 3 or 6. However, attempts to identify a unique AMH type I receptor among them were unsuccessful. Here, using kinase-deficient type I receptors and small interfering RNA technology, we demonstrate that, in an AMH Sertoli target cell line, ALK3 mediates AMH effects on both Smad1 activation and P450 side-chain cleavage enzyme. In addition, transfecting a combination of normal and kinase-deficient receptors, we show that ALK2 can compensate for the absence of ALK3 and probably acts in synergy with ALK3 at high concentrations of AMH to activate Smad1, whereas ALK6 has a competitive inhibitory effect. These results are a first step in understanding how AMH transduces its effects in immature Sertoli cells.

Details

Language :
English
ISSN :
09509232 and 14765594
Database :
OpenAIRE
Journal :
Oncogene, Oncogene, Nature Publishing Group, 2005, 24 (31), pp.4984-4992. ⟨10.1038/sj.onc.1208686⟩, Oncogene, 2005, 24 (31), pp.4984-4992. ⟨10.1038/sj.onc.1208686⟩
Accession number :
edsair.doi.dedup.....b4466a9ac931e1a5bdcc5f527b73f65c
Full Text :
https://doi.org/10.1038/sj.onc.1208686⟩